[1] Retatrutide (trials): once-weekly subcutaneous administration, starting low (e.g., 2 mg) and escalating to 4, 8, or 12 mg maintenance, with slower titration used to improve tolerability
However, because everyones internal chemistry is unique, some individuals may experience mild shifts as their body adjusts
These are not small risks
The scienceand the regulationare not
however, CS exposure reduces Nrf2 activity, leading to decreased expression of antioxidant genes and insufficient production of endogenous antioxidants
almost all the HFs in the chosen region targeted for quantifications were labeled, and we did not detect any leaky induction in the absence of Tamoxifen injection (Figure 1figure supplement 2D-G)